ReviewMediators of inflammation2014
Interleukin-33 and inflammatory bowel diseases: lessons from human studies.
Review in Mediators of inflammation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 41 citations in OpenAlex.
- Cytokine and chemokine networks in colorectal cancer.Frontiers in immunology · 2026Review
- Genetic Regulation of Immune Response in Dogs.Genes · 2025Review
- Associations ofHeliyon · 2024Article
- Inflammatory biomarkers and physiomarkers of late-onset sepsis and necrotizing enterocolitis in premature infants.Frontiers in pediatrics · 2024Article
- Expression of IL-21 and IL-33 in Intestinal Mucosa of Inflammatory Bowel Disease: An Immunohistochemical Study.Diagnostics (Basel, Switzerland) · 2023Article
- Paradoxical role of interleukin-33/suppressor of tumorigenicity 2 in colorectal carcinogenesis: Progress and therapeutic potential.World journal of clinical cases · 2022Review
- The Interleukin-1 (IL-1) Superfamily Cytokines and Their Single Nucleotide Polymorphisms (SNPs).Journal of immunology research · 2022Review
- Myeloid-Derived IL-33 Limits the Severity of Dextran Sulfate Sodium-Induced Colitis.The American journal of pathology · 2021Article
- IL-33 Drives Expansion of Type 2 Innate Lymphoid Cells and Regulatory T Cells and Protects Mice From Severe, Acute Colitis.Frontiers in immunology · 2021Article
- Dual immune functions of IL-33 in inflammatory bowel disease.Histology and histopathology · 2020Review
- Protective effect of TSLP and IL-33 cytokines in ulcerative colitis.Auto- immunity highlights · 2019Article
- IL33: Roles in Allergic Inflammation and Therapeutic Perspectives.Frontiers in immunology · 2019Review
- Baicalein Mitigates Radiation-Induced Enteritis by Improving Endothelial Dysfunction.Frontiers in pharmacology · 2019Article
- Damage-associated molecular patterns in inflammatory bowel disease: From biomarkers to therapeutic targets.World journal of gastroenterology · 2018Review
- Interleukin 33 regulates gene expression in intestinal epithelial cells independently of its nuclear localization.Cytokine · 2018Article
- The Role of IL-33/ST2 Pathway in Tumorigenesis.International journal of molecular sciences · 2018Review
- The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.International journal of molecular sciences · 2017Review
- Dectin-1 signaling inhibits osteoclastogenesis via IL-33-induced inhibition of NFATc1.Oncotarget · 2017Article
- Epithelial-derived IL-33 promotes intestinal tumorigenesis in ApcScientific reports · 2017Article
- Expression of epithelial cell-derived cytokine genes in the duodenal and colonic mucosae of dogs with chronic enteropathy.The Journal of veterinary medical science · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin- (IL-) 33 is a widely expressed cytokine present in different cell types, such as epithelial, mesenchymal, and inflammatory cells, supporting a predominant role in innate immunity. IL-33 can function as a proinflammatory cytokine inducing Th2 type of immune response being involved with the defense against parasitic infections of the gastrointestinal tract. In addition, it has been proposed that IL-33 can act as a signaling molecule alerting the immune system of danger or tissue damage. Recently, in the intestinal mucosa, overexpression of IL-33 has been reported in samples from patients with inflammatory bowel diseases (IBD). This review highlights the available data regarding IL-33 in human IBD and discusses emerging roles for IL-33 as a key modulator of intestinal inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.